NeuroMetrix Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.7346
- Today's High:
- $0.7999
- Open Price:
- $0.746
- 52W Low:
- $0.64
- 52W High:
- $3.5
- Prev. Close:
- $0.73
- Volume:
- 70645
Company Statistics
- Market Cap.:
- $6.30 million
- Book Value:
- 2.496
- Revenue TTM:
- $7.20 million
- Operating Margin TTM:
- -82.03%
- Gross Profit TTM:
- $5.75 million
- Profit Margin:
- -75.17%
- Return on Assets TTM:
- -15.36%
- Return on Equity TTM:
- -24.14%
Company Profile
NeuroMetrix Inc had its IPO on 2001-01-02 under the ticker symbol NURO.
The company operates in the Healthcare sector and Medical Devices industry. NeuroMetrix Inc has a staff strength of 27 employees.
Stock update
Shares of NeuroMetrix Inc opened at $0.75 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.73 - $0.8, and closed at $0.73.
This is a +0.63% increase from the previous day's closing price.
A total volume of 70,645 shares were traded at the close of the day’s session.
In the last one week, shares of NeuroMetrix Inc have increased by +0.63%.
NeuroMetrix Inc's Key Ratios
NeuroMetrix Inc has a market cap of $6.30 million, indicating a price to book ratio of 0.565 and a price to sales ratio of 1.414.
In the last 12-months NeuroMetrix Inc’s revenue was $7.20 million with a gross profit of $5.75 million and an EBITDA of $-5859424. The EBITDA ratio measures NeuroMetrix Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, NeuroMetrix Inc’s operating margin was -82.03% while its return on assets stood at -15.36% with a return of equity of -24.14%.
In Q2, NeuroMetrix Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.6%.
NeuroMetrix Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -0.01
Its diluted EPS in the last 12-months stands at $-0.7 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.01. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NeuroMetrix Inc’s profitability.
NeuroMetrix Inc stock is trading at a EV to sales ratio of 0.245 and a EV to EBITDA ratio of 1.6468. Its price to sales ratio in the trailing 12-months stood at 1.414.
NeuroMetrix Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $22.77 million
- Total Liabilities
- $1.21 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
NeuroMetrix Inc ended 2024 with $22.77 million in total assets and $0 in total liabilities. Its intangible assets were valued at $22.77 million while shareholder equity stood at $21.41 million.
NeuroMetrix Inc ended 2024 with $0 in deferred long-term liabilities, $1.21 million in other current liabilities, 858.00 in common stock, $-206691069.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.86 million and cash and short-term investments were $19.63 million. The company’s total short-term debt was $148,391 while long-term debt stood at $0.
NeuroMetrix Inc’s total current assets stands at $22.29 million while long-term investments were $0 and short-term investments were $16.77 million. Its net receivables were $746725.00 compared to accounts payable of $181462.00 and inventory worth $1.58 million.
In 2024, NeuroMetrix Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, NeuroMetrix Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.73
- 52-Week High
- $3.5
- 52-Week Low
- $0.64
- Analyst Target Price
- $50
NeuroMetrix Inc stock is currently trading at $0.73 per share. It touched a 52-week high of $3.5 and a 52-week low of $3.5. Analysts tracking the stock have a 12-month average target price of $50.
Its 50-day moving average was $0.85 and 200-day moving average was $1.3 The short ratio stood at 0.29 indicating a short percent outstanding of 0%.
Around 199.8% of the company’s stock are held by insiders while 858.6% are held by institutions.
Frequently Asked Questions About NeuroMetrix Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.